dendritic cell immunotherapy

Diakonos Oncology is a clinical-stage biotechnology company developing a Dendritic Cell Vaccine (DCV) called DOC1021 (also known as dubodencel) for difficult-to-treat cancers. Its proprietary patented 'double-loading' technique tricks the body into perceiving cancer cells as virally infected cells. The company received FDA Fast Track designation and is based on research conducted at Baylor College of Medicine, working with institutions such as MD Anderson and UTHealth Houston.

Read more

clinical trialsdouble-loading vaccine technique